Société ADWYA S.A produces and sells pharmaceutical products in Tunisia.
Price History & Performance
|Historical stock prices|
|Current Share Price||د.ت4.26|
|52 Week High||د.ت3.89|
|52 Week Low||د.ت5.28|
|1 Month Change||-9.36%|
|3 Month Change||-16.31%|
|1 Year Change||0.24%|
|3 Year Change||-7.39%|
|5 Year Change||-17.27%|
|Change since IPO||108.43%|
Recent News & Updates
|ADWYA||TN Pharmaceuticals||TN Market|
Return vs Industry: ADWYA underperformed the TN Pharmaceuticals industry which returned 89.6% over the past year.
Return vs Market: ADWYA matched the TN Market which returned 0.3% over the past year.
Stable Share Price: ADWYA is more volatile than 75% of TN stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: ADWYA's weekly volatility (5%) has been stable over the past year, but is still higher than 75% of TN stocks.
About the Company
Société ADWYA S.A produces and sells pharmaceutical products in Tunisia. The company was founded in 1983 and is headquartered in La Marsa, Tunisia.
Société ADWYA Fundamentals Summary
|ADWYA fundamental statistics|
Is ADWYA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ADWYA income statement (TTM)|
|Cost of Revenue||د.ت54.96m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.10|
|Net Profit Margin||-2.54%|
How did ADWYA perform over the long term?See historical performance and comparison
2.3%Current Dividend Yield
Is Société ADWYA undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ADWYA (TND4.26) is trading below our estimate of fair value (TND24.39)
Significantly Below Fair Value: ADWYA is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ADWYA is unprofitable, so we can't compare its PE Ratio to the African Pharmaceuticals industry average.
PE vs Market: ADWYA is unprofitable, so we can't compare its PE Ratio to the TN market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ADWYA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ADWYA is overvalued based on its PB Ratio (2.6x) compared to the XF Pharmaceuticals industry average (1.6x).
How is Société ADWYA forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Société ADWYA has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Société ADWYA performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ADWYA is currently unprofitable.
Growing Profit Margin: ADWYA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ADWYA is unprofitable, and losses have increased over the past 5 years at a rate of 26.5% per year.
Accelerating Growth: Unable to compare ADWYA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ADWYA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (10%).
Return on Equity
High ROE: ADWYA has a negative Return on Equity (-6.36%), as it is currently unprofitable.
How is Société ADWYA's financial position?
Financial Position Analysis
Short Term Liabilities: ADWYA's short term assets (TND84.7M) exceed its short term liabilities (TND81.0M).
Long Term Liabilities: ADWYA's short term assets (TND84.7M) exceed its long term liabilities (TND14.5M).
Debt to Equity History and Analysis
Debt Level: ADWYA's debt to equity ratio (137.7%) is considered high.
Reducing Debt: ADWYA's debt to equity ratio has increased from 35.3% to 137.7% over the past 5 years.
Debt Coverage: ADWYA's debt is well covered by operating cash flow (58.2%).
Interest Coverage: ADWYA's interest payments on its debt are not well covered by EBIT (1x coverage).
What is Société ADWYA current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: ADWYA's dividend (2.35%) isn’t notable compared to the bottom 25% of dividend payers in the TN market (2.91%).
High Dividend: ADWYA's dividend (2.35%) is low compared to the top 25% of dividend payers in the TN market (6.68%).
Stability and Growth of Payments
Stable Dividend: Too early to tell whether ADWYA's dividend payments have been stable as they only just started paying a dividend.
Growing Dividend: Too early to tell if ADWYA's dividend payments are increasing as they only just started paying a dividend.
Current Payout to Shareholders
Dividend Coverage: ADWYA is paying a dividend but the company is unprofitable.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Société ADWYA has no CEO, or we have no data on them.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Société ADWYA S.A's employee growth, exchange listings and data sources
- Name: Société ADWYA S.A
- Ticker: ADWYA
- Exchange: BVMT
- Founded: 1983
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: د.ت97.952m
- Shares outstanding: 21.53m
- Website: https://www.adwya.com.tn
Number of Employees
- Société ADWYA S.A
- Route de la Marsa Km 14
- BP 658
- La Marsa
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/20 15:28|
|End of Day Share Price||2021/10/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.